[耐多药结核分枝杆菌复合群菌株中利福平和利福布汀之间的交叉耐药性]

[Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains].

作者信息

Gao Li, Xiao He-ping, Hu Zhong-yi, Cui Zhen-ling, Lu Jun-mei, Shen Xiao-na

机构信息

School of Medicine, Soochow University, Suzhou 215123, China.

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):333-5.

PMID:22883990

Abstract

OBJECTIVE

To study the cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains, and therefore to provide laboratory data for using rifabutin in the treatment of multidrug resistant tuberculosis.

METHODS

The MIC(90) of rifabutin and rifampin against 99 multidrug resistant Mycobacterium tuberculosis clinical strains were determined by microplate assays. Statistical analysis was performed by using the χ(2) test and the t test.

RESULTS

The cross-resistance rate between rifampicin and rifabutin was 85.9% (85/99), but the MIC(90) of rifabutin (≤ 16 mg/L, median 2 mg/L) was significantly lower than that of rifampicin (≥ 2 mg/L, median > 32 mg/L). The cross-resistance rate increased with the resistance level of rifampicin. The cross-resistance strains in the lower and the medium groups were 0/9 and 5/9 respectively, while the strains of the high rifampicin-resistant group were almost all cross-resistant (98.8%, 80/81).

CONCLUSION

Rifabutin had activities against rifampin resistant Mycobacterium tuberculosis complex strains in vitro, and therefore may be used as an alternative for the treatment of multidrug resistant tuberculosis.

摘要

目的

研究多药耐药结核分枝杆菌复合群菌株中利福平和利福布汀之间的交叉耐药性，从而为利福布汀用于治疗多药耐药结核病提供实验室数据。

方法

采用微孔板法测定利福布汀和利福平对99株多药耐药结核分枝杆菌临床分离株的MIC(90)。采用χ(2)检验和t检验进行统计学分析。

结果

利福平和利福布汀之间的交叉耐药率为85.9%（85/99），但利福布汀的MIC(90)（≤16mg/L，中位数2mg/L）显著低于利福平（≥2mg/L，中位数>32mg/L）。交叉耐药率随利福平耐药水平的升高而增加。低耐药组和中耐药组的交叉耐药菌株分别为0/9和5/9，而高耐利福平组的菌株几乎全部交叉耐药（98.8%，80/81）。